Article Sidebar

PDF
Date Published: 31/07/2022
Abstract Views: 206
Views PDF: 205
DOI: https://doi.org/10.51298/vmj.v516i2.3047
Issue
Vol. 516 No. 2 (2022)
Section
Các bài báo
How to Cite
Hùng Kiên, Đỗ . (2022). THE ADVERSE EVENTS OF ADJUVANT CHEMOTHERAPY OF VINORELBIN PLUS CISPLATIN FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 516(2). https://doi.org/10.51298/vmj.v516i2.3047

THE ADVERSE EVENTS OF ADJUVANT CHEMOTHERAPY OF VINORELBIN PLUS CISPLATIN FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER

Đỗ Hùng Kiên1,
1 K Hospital

Main Article Content

Abstract

Objective: Analyzing the adverse events of adjuvant chemotherapy vinorelbine plus cisplatin in completed resected non-small cell lung cancer at National Cancer Hospital from 2016 to 2021. Patients and method: Retrospective and prospective analysis of 66 patients with stage IB-IIIA resesected non-small cell lung cancer were received adjuvant vinorelbine plus cisplatin chemotherapy from K hospital, 01/2016 to 10/2021. Results: All of patients were received 4 cycles of vinorelbin plus cisplatin regimen adjuvant chemotherapy, there was no report of stopping treatment because of toxicities. There were 26 patients presented delays during adjuvant chemotherapy. There was no report of decreased doses of chemotherapy in our study. The myelosuppresstion was frequent and neutropenia was the most common (accounting for 61.2%), including grade-III, IV neutropenia accounted for 28.1%, rate of anemia was 45.8%. Major non-hematologic toxic effects were nausea/vomiting and alopecia, usually grade I-II. There was one patient presented with grade IV of elevated hepatic enzymes during treatment. Conclusion: Adjuvant chemotherapy of regimen vinorelbin plus cisplatin showed good tolerance in patients with non-small cell lung cancer

Article Details

Keywords

Non small cell lung cancer, vinorelbine, cisplatin, adjuvant chemotherapy NSCLC

References

1. GS.TS Trần Văn Thuấn Ung thư phổi không tế bào nhỏ. Hướng dẫn chẩn đoán và điều trị bệnh ung thư thường gặp. Nhà xuất bản Y học, Hà Nội, 92–105.
2. Douillard J.-Y., Tribodet H., Aubert D. và cộng sự. (2010). Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol, 5(2), 220–228.
3. Winton T., Livingston R., Johnson D. và cộng sự. (2005). Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. N Engl J Med, 352(25), 2589–2597.
4. Moumtzi D., Lampaki S., Zarogoulidis P. và cộng sự. (2016). Prognostic factors for long term survival in patients with advanced non-small cell lung cancer. Ann Transl Med, 4(9).
5. Douillard J.-Y., Rosell R., De Lena M. và cộng sự. (2006). Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 7(9), 719–727.
6. Shukuya T., Takahashi T., Tamiya A. và cộng sự. (2009). Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study. Jpn J Clin Oncol, 39(3), 158–162.
7. Douillard J.-Y., Gervais R., Dabouis G. và cộng sự. (2005). Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol, 16(1), 81–89.
8. Douillard J.-Y., Tribodet H., Aubert D. và cộng sự. (2010). Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol, 5(2), 220–228.